基于结构的发现,一种新型的支架化合物作为与蛋白质结合的尿素毒素的结合竞争者
Ping Wang1,2, Shasha Liu1, Shengtian Zhao3
1Institute of Medical Artificial Intelligence, Binzhou Medical University, Yantai, 264003, P.R., China.
Scientific reports
|November 15, 2024
概括
新的候选药物在去除导致尿血的蛋白质结合尿素毒素 (PBUTs) 方面表现有前途. 这些化合物显示出比目前的透析方法更高的透析效率,为改善尿血症治疗提供了希望.
科学领域:
- 药用化学 医学化学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 计算机化药物发现技术
背景情况:
- 蛋白质结合尿素毒素 (PBUTs) 是尿血的主要贡献者.
- 传统的血液透析很难去除PBUTs,因为它们与人血清白蛋白 (HSA) 具有很高的结合亲和力.
- 新的治疗策略对于有效的PBUT去除至关重要.
研究的目的:
- 确定能够从HSA中取代PBUTs的新型化合物.
- 通过针对PBUTs来开发更有效的尿血治疗方法.
主要方法:
- 基于结构的虚拟选超过20万个化合物.
- 预测ADMET,毒性分析和MM-PBSA计算候选精炼剂.
- 微透析实验以评估与HSA绑定的PBUT相比的竞争性排位效率.
主要成果:
- 三种化合物 (ZINC000008791789,ZINC000012297018,ZINC000012296493) 与最佳排位器LA.相比,表现出更高的透析效率.
- 另外两种化合物 (ZINC000031161007,ZINC000004090361) 也显示出比对照组更好的性能.
- 在最有效的化合物中确定了常见的分子支架和一个黄类组.
结论:
- 确定了有前途的化合物,用于开发有效的PBUT结合竞争者.
- 这些发现为新型治疗药物管理尿血症奠定了基础.
- 对患有尿血病的患者有显著临床益处的潜力.
相关概念视频
Protein-Drug Binding: Determination Methods
134
Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
134
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
Drug Distribution: Plasma Protein Binding
4.9K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
4.9K
Protein-protein Interfaces
12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
Drug Elimination by Renal Route: Tubular Secretion
2.2K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.2K
Enzyme Inhibition
77.9K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.9K


